Results You Can See and Feel
–That’s a Win for Skin

Backed by science, DUPIXENT is the first FDA-approved treatment for prurigo nodularis (PN).

 

CLINICAL TRIAL RESULTS

In two clinical studies with 311 adults with PN:

At 24 Weeks
59%
HAD NOTICEABLY
LESS ITCH

59% on DUPIXENT vs 19% not on DUPIXENT

At 24 Weeks
46%
SAW SKIN CLEAR OR ALMOST CLEAR OF PN BUMPS

46% on DUPIXENT vs 17% not on DUPIXENT

At 24 Weeks
46%
SAW SKIN CLEAR OR ALMOST CLEAR OF PN BUMPS

46% on DUPIXENT vs 17% not on DUPIXENT

At 24 Weeks
59%
HAD NOTICEABLY
LESS ITCH

59% on DUPIXENT vs 19% not on DUPIXENT

IN ONE STUDY:

In As Little As 12 Weeks
37%
EXPERIENCED
LESS ITCH

37% on DUPIXENT vs 22% not on DUPIXENT

VIEW SAFETY RESULTS

MOST COMMON SIDE EFFECTS IN PATIENTS WITH PRURIGO NODULARIS INCLUDE:

  • Eye and eyelid inflammation, including redness,
    swelling, and itching, sometimes with blurred vision
  • Herpes virus infections
  • Common cold symptoms (nasopharyngitis)
  • Dizziness
  • Muscle pain
  • Diarrhea

 

View Before and After Results With DUPIXENT

Results with 32 weeks of treatment with DUPIXENT

Click and drag
to see results
Click and drag
to see results

Actual patient shown. Additional factors (including possible use of other treatments) may have impacted results. Individual results may vary.

Prior to starting DUPIXENT, I was uncomfortable about the many
nodules on my arms and legs.

Brooke,
Actual DUPIXENT patient.
Individual results may vary.

Hear Brooke’s story

A Helpful Reminder

Get valuable info from this video to help you during your treatment journey.

Prepare For Your Doctor Appointment

You have a lot of questions and deserve to get the right answers. Our personalized
discussion guide lets you document your symptoms and severity so you can have a
more productive conversation with your doctor.
Start your guide